Ozempic (semaglutide) offers significant benefits for blood sugar control and cardiovascular protection, but it comes with real trade-offs: persistent gastrointestinal side effects, high cost, substantial weight regain if you stop, and notable muscle loss alongside fat loss. Whether the pros outweigh the cons depends on your health situation, your budget, and how long you plan to stay on the medication.
Blood Sugar Control
Ozempic’s primary purpose is managing type 2 diabetes, and it performs well. In clinical trials, patients taking the 1 mg dose saw their A1c drop by 1.5 to 2.2 percentage points over 30 to 56 weeks, depending on whether they were using it alone or alongside other medications. For context, an A1c drop of even 1 point is clinically meaningful, so reductions approaching 2 points represent a major shift in blood sugar management.
The lower 0.5 mg dose also produced strong results, with A1c reductions ranging from about 1.1 to 1.9 percentage points across trials. Both doses consistently outperformed placebo and several older diabetes medications.
Cardiovascular Benefits
Beyond blood sugar, semaglutide has shown a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in the SELECT trial, which studied patients with obesity and established heart disease. This is a meaningful benefit for people already at elevated cardiovascular risk, and it’s one of the reasons Ozempic has attracted attention well beyond the diabetes community.
Weight Loss
Most people on Ozempic lose weight, often substantially. The drug works by mimicking a gut hormone that slows digestion, reduces appetite, and changes how your brain responds to food cues. In diabetes trials, weight loss is a consistent secondary benefit. The higher-dose version of semaglutide marketed specifically for weight loss (Wegovy) produced an average loss of about 15% of body weight in the STEP-1 trial.
But the weight loss story has a significant catch, which brings us to the cons.
Weight Regain After Stopping
Ozempic is not a short-term fix. A systematic review published in The Lancet found that at one year after stopping a GLP-1 drug like semaglutide, patients had regained 60% of the weight they lost during treatment. This means most people need to stay on the medication indefinitely to maintain results, which has major implications for both cost and long-term side effect exposure.
Muscle Loss Is a Real Concern
Not all the weight you lose on Ozempic is fat. Data from the STEP-1 trial showed that roughly 45% of total weight lost came from lean mass rather than fat. In practical terms, participants lost about 7 kg of lean mass out of a total 15.3 kg lost. Lean mass includes muscle, and losing that much can affect strength, metabolism, and physical function, particularly in older adults.
This is why many clinicians now recommend combining semaglutide with resistance training and higher protein intake to preserve as much muscle as possible during treatment.
Gastrointestinal Side Effects
Nausea, vomiting, diarrhea, abdominal pain, and constipation are the most common side effects, each occurring in 5% or more of patients. These symptoms tend to be worst during the dose escalation period, when you’re gradually increasing from the starter dose to your maintenance dose over several weeks. For most people, the nausea fades or becomes manageable over time.
Still, about 3 to 4% of patients in clinical trials discontinued the drug because of gastrointestinal problems. Higher doses produce more GI issues: 34% of patients on the 2 mg dose experienced gastrointestinal side effects compared to about 31% on the 1 mg dose. Some people find the nausea mild and temporary. Others find it disruptive enough to stop treatment.
Serious but Rare Risks
Ozempic carries an FDA boxed warning, the most serious type, related to thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors in rodents. Whether this translates to humans remains unknown, but the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Pancreatitis is another risk, though the numbers in clinical trials were low. In glycemic control studies, acute pancreatitis occurred at a rate of about 0.3 cases per 100 patient-years on Ozempic versus 0.2 cases per 100 patient-years on comparator treatments. In a two-year trial, rates were actually similar between semaglutide and placebo. The risk is real but small, and symptoms like severe, persistent abdominal pain warrant immediate medical attention.
Cost and Access
Ozempic is expensive. The list price is over $1,000 per pen. For new patients paying out of pocket, Novo Nordisk offers an introductory price of $199 per month for the first two months, but after that the standard cost without insurance is $349 per month for the 0.5 mg or 1 mg doses, and $499 per month for the 2 mg dose.
Insurance coverage varies widely. Many plans cover Ozempic for type 2 diabetes but not for weight loss alone. Some insurers require prior authorization or documentation that other treatments have failed. Given that most people need to take the drug long-term to maintain benefits, the cumulative cost can reach thousands of dollars per year even with insurance.
How Dosing Works
Ozempic is a once-weekly injection you give yourself, typically in the abdomen, thigh, or upper arm. You start at 0.25 mg weekly for four weeks, a dose that’s only meant to let your body adjust and doesn’t provide meaningful blood sugar control on its own. After that, you move up to 0.5 mg. If your blood sugar still isn’t well controlled after at least another four weeks, your dose can be increased to 1 mg weekly.
This gradual ramp-up is designed to minimize the gastrointestinal side effects that tend to hit hardest when the drug is first introduced. Skipping the escalation period or increasing too quickly generally makes nausea and vomiting worse.
Who Benefits Most
The strongest case for Ozempic is in people with type 2 diabetes who need better blood sugar control, especially those who also have cardiovascular risk factors. The dual benefit of A1c reduction and heart protection makes it a compelling option for this group. People with obesity who have struggled with other weight loss approaches may also benefit, though the muscle loss and weight regain issues deserve serious consideration.
The weakest case is for someone looking for a short-term weight loss tool with plans to stop after reaching a goal weight. The data on regain suggest that approach is unlikely to produce lasting results, and you’ll have absorbed the cost and side effects with little to show for it long-term.